Work

Phase 1 dose escalation study of SL-172154 (SIRPα-Fc-CD40L) in platinum-resistant ovarian cancer.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.5544

Authors: Nehal J. Lakhani, Daphne B. Stewart, Debra L. Richardson, Lauren E. Dockery, Linda Van Le, Justin A Call, Fatima A. Rangwala, Anya Scholl, Guanfang Wang, Bo Ma, Simon Metenou, Louis Gonzalez, Arundathy Pandite, Erika P. Hamilton

Institutions: City Of Hope National Medical Center, OU Health Stephenson Cancer Center, University of Oklahoma, University of North Carolina at Chapel Hill, Sarah Cannon, Tennessee Oncology

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4379281758

Cites:

Cited by: 9

Related to: 10